Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis

NCT06700343 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06700343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06700343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 13, 2025
Completion date
October 4, 2027
Enrollment
152 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis (rrms)